je.st
news
Tag: investment
British Columbia Investment Management Corp Increases Position in AutoZone, Inc.
2016-02-02 01:34:01| Auto Parts - Topix.net
British Columbia Investment Management Corp raised its position in shares of AutoZone, Inc. by 3.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 17,540 shares of the company's stock after buying an additional 650 shares during the period.
Tags: inc
management
position
british
Zacks Investment Research Reaffirms "Hold" Rating for Rackspace Hosting, Inc.
2016-02-01 17:46:42| IT Services - Topix.net
's stock had its "hold" rating reiterated by Zacks Investment Research in a report issued on Monday, MarketBeat Ratings reports. According to Zacks, "As the world's leader and specialist in hosting, Rackspace Hosting is changing the way businesses worldwide buy IT.
Tags: inc
research
rating
hold
Dean Foods Co (DF) Stake Cut by BRC Investment Management LLC
2016-02-01 16:02:24| Food - Topix.net
BRC Investment Management LLC cut its position in Dean Foods Co by 0.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The firm owned 43,819 shares of the company's stock after selling 61 shares during the period.
Tags: management
llc
cut
investment
Oshkosh Co. (OSK) Rating Increased to Hold at Zacks Investment Research
2016-02-01 11:47:21| Automakers - Topix.net
According to Zacks, "Oshkosh Corporation is a leading designer, manufacturer and marketer of a broad range of specialty access equipment, commercial, fire & emergency and military vehicles and vehicle bodies. Oshkosh Corporation manufactures, distributes and services products under the brands of Oshkosh, JLG, Pierce, McNeilus, Medtec, Jerr-Dan, BAI, Oshkosh Specialty Vehicles, Frontline, SMIT, Geesink, Norba, Kiggen, Con-E-Co, London and IMT.
Tags: research
rating
hold
increased
Zacks Investment Research Reaffirms "Buy" Rating for OncoGenex Pharmaceuticals Inc
2016-02-01 10:16:39| Biotech - Topix.net
's stock had its "buy" rating restated by Zacks Investment Research in a report released on Sunday, AnalystRatingsNetwork.com reports. They currently have a $0.75 target price on the biopharmaceutical company's stock.
Sites : [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] [381] [382] [383] [384] [385] [386] [387] [388] [389] [390] next »